{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T04:01:12Z","timestamp":1746936072565,"version":"3.40.5"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100016834","name":"Chongqing Municipal Health Commission","doi-asserted-by":"publisher","award":["2023MSXM117"],"award-info":[{"award-number":["2023MSXM117"]}],"id":[{"id":"10.13039\/100016834","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Shapingba District Technology Innovation Project","award":["2024122"],"award-info":[{"award-number":["2024122"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The diagnosis and prognosis of hepatocellular carcinoma (HCC) present significant challenges in clinical practice. This study aimed to evaluate the clinical utility of tumor abnormal protein (TAP), Prothrombin induced by vitamin K absence-II (PIVKA-II), and alpha-fetoprotein (AFP) in diagnosing HCC as well as to investigate their prognostic significance in patients with HCC undergoing transarterial chemoembolization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 93 HCC patients were enrolled and 101 healthy individuals served as controls. Fresh venous blood samples were collected, and TAP, PIVKA-II, and AFP levels were measured by chemiluminescence immunoassay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Significant differences in TAP, PIVKA-II, and AFP levels were found between HCC patients and healthy individuals. The combined assay of TAP, AFP, and PIVKA-II showed better diagnostic performance for HCC. Patients who underwent transarterial chemoembolization and achieved complete response (CR) had lower levels of prechemotherapy serum TAP, AFP, and PIVKA-II. There are significant differences in levels of TAP, AFP, and PIVKA-II between CR and partial response (PR), CR and stable disease (SD), and CR and progressive disease (PD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Combined detection of TAP, PIVKA-II, and AFP has better diagnostic performance for HCC. Higher levels of prechemotherapy serum TAP, AFP, and PIVKA-II are significantly associated with poor clinical chemoresponse.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/labmed\/lmae104","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:46:01Z","timestamp":1735897561000},"page":"297-304","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic value of TAP, PIVKA-II, and AFP in hepatocellular carcinoma and their prognostic value for patients treated with transarterial chemoembolization"],"prefix":"10.1093","volume":"56","author":[{"given":"Delu","family":"Gan","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, the Second Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yali","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital , Chongqing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Oncology, Chongqing University Cancer Hospital , Chongqing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Information Center, the Second Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, the Second Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianqin","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital , Chongqing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-3143","authenticated-orcid":false,"given":"Pu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, the Second Affiliated Hospital of Chongqing Medical University , Chongqing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4212-5971","authenticated-orcid":false,"given":"Dan","family":"Gou","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital , Chongqing ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"issue":"1","key":"2025051000265304500_CIT0001","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol."},{"issue":"2","key":"2025051000265304500_CIT0002","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin."},{"issue":"5","key":"2025051000265304500_CIT0003","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer."},{"issue":"1","key":"2025051000265304500_CIT0004","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000082091","article-title":"How to predict HCC development in patients with chronic B viral liver disease","volume":"48","author":"Han","year":"2005","journal-title":"Intervirology."},{"issue":"2","key":"2025051000265304500_CIT0005","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/1097-0142(197708)40:2&lt;779::aid-cncr2820400227&gt;3.0.co;2-y","article-title":"Serum alphafetoprotein in hepatocellular carcinoma","volume":"40","author":"Chen","year":"1977","journal-title":"Cancer."},{"issue":"12","key":"2025051000265304500_CIT0006","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1111\/liv.14223","article-title":"Biology and significance of alpha-fetoprotein in hepatocellular carcinoma","volume":"39","author":"Galle","year":"2019","journal-title":"Liver Int."},{"key":"2025051000265304500_CIT0007","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cca.2016.10.006","article-title":"Alpha-foetoprotein (AFP): a multi-purpose marker in hepatocellular carcinoma","volume":"463","author":"Sauzay","year":"2016","journal-title":"Clin Chim Acta."},{"issue":"1","key":"2025051000265304500_CIT0008","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/s1089-3261(05)70158-6","article-title":"The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma","volume":"5","author":"Johnson","year":"2001","journal-title":"Clin Liver Dis."},{"issue":"1","key":"2025051000265304500_CIT0009","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7326\/0003-4819-139-1-200307010-00012","article-title":"Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis","volume":"139","author":"Gupta","year":"2003","journal-title":"Ann Intern Med."},{"issue":"8","key":"2025051000265304500_CIT0010","first-page":"2350","article-title":"Serum NOX2 as a new biomarker candidate for HBV-related disorders","volume":"10","author":"Xiong","year":"2018","journal-title":"Am J Transl Res"},{"key":"2025051000265304500_CIT0011","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2147\/CMAR.S167036","article-title":"Direct comparison of five serum biomarkers in early diagnosis of hepatocellular carcinoma","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"3","key":"2025051000265304500_CIT0012","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/1724600818760234","article-title":"Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: a systematic review and meta-analysis","volume":"33","author":"Zhang","year":"2018","journal-title":"Int J Biol Markers."},{"issue":"6","key":"2025051000265304500_CIT0013","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nrd1751","article-title":"Glycans in cancer and inflammation\u2013potential for therapeutics and diagnostics","volume":"4","author":"Dube","year":"2005","journal-title":"Nat Rev Drug Discov."},{"issue":"9","key":"2025051000265304500_CIT0014","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.7314\/apjcp.2015.16.9.4041","article-title":"Clinical application of serum tumor abnormal protein from patients with gastric cancer","volume":"16","author":"Liu","year":"2015","journal-title":"Asian Pac J Cancer Prev."},{"issue":"5","key":"2025051000265304500_CIT0015","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00432-014-1806-0","article-title":"Management of hepatocellular carcinoma","volume":"141","author":"Fitzmorris","year":"2015","journal-title":"J Cancer Res Clin Oncol."},{"issue":"8","key":"2025051000265304500_CIT0016","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/clinchem\/29.8.1474","article-title":"Acridinium esters as high-specific-activity labels in immunoassay","volume":"29","author":"Weeks","year":"1983","journal-title":"Clin Chem."},{"issue":"8","key":"2025051000265304500_CIT0017","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/clinchem\/29.8.1480","article-title":"Two-site immunochemiluminometric assay for human alpha 1-fetoprotein","volume":"29","author":"Weeks","year":"1983","journal-title":"Clin Chem."},{"issue":"2","key":"2025051000265304500_CIT0018","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cca.2008.03.010","article-title":"Development of high-performance magnetic chemiluminescence enzyme immunoassay for alpha-fetoprotein (AFP) in human serum","volume":"393","author":"Wang","year":"2008","journal-title":"Clin Chim Acta."},{"issue":"17-18","key":"2025051000265304500_CIT0019","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.clinbiochem.2011.08.1144","article-title":"Evaluation of automated serum des-gamma-carboxyprothrombin (DCP) assays for detecting hepatocellular carcinoma","volume":"44","author":"Choi","year":"2011","journal-title":"Clin Biochem."},{"issue":"3","key":"2025051000265304500_CIT0020","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/j.1572-0241.1999.00930.x","article-title":"Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma","volume":"94","author":"Nomura","year":"1999","journal-title":"Am J Gastroenterol."},{"issue":"5 Suppl 1","key":"2025051000265304500_CIT0021","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1053\/j.gastro.2004.09.023","article-title":"Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma","volume":"127","author":"Daniele","year":"2004","journal-title":"Gastroenterology."},{"issue":"6","key":"2025051000265304500_CIT0022","first-page":"295","article-title":"Screening of hepatocellular carcinoma: role of the alpha-fetoprotein (AFP) and ultrasonography","volume":"96","author":"Barletta","year":"2005","journal-title":"Recent Prog Med."},{"issue":"2","key":"2025051000265304500_CIT0023","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology."},{"issue":"9","key":"2025051000265304500_CIT0024","first-page":"2993","article-title":"Recent progress in treatment of hepatocellular carcinoma","volume":"10","author":"Chen","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"5","key":"2025051000265304500_CIT0025","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jhep.2015.02.010","article-title":"Transarterial chemoembolization: modalities, indication, and patient selection","volume":"62","author":"Sieghart","year":"2015","journal-title":"J Hepatol."},{"issue":"2","key":"2025051000265304500_CIT0026","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11523-019-00624-w","article-title":"The changing landscape of systemic treatment of advanced hepatocellular carcinoma: new targeted agents and immunotherapies","volume":"14","author":"Marquardt","year":"2019","journal-title":"Target Oncol"},{"issue":"4","key":"2025051000265304500_CIT0027","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol Int"},{"issue":"6","key":"2025051000265304500_CIT0028","doi-asserted-by":"publisher","first-page":"387","DOI":"10.21037\/hbsn.2017.11.01","article-title":"Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma","volume":"6","author":"Xie","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"7","key":"2025051000265304500_CIT0029","doi-asserted-by":"publisher","first-page":"e28806","DOI":"10.5812\/hepatmon.28806v2","article-title":"Performance of Protein induced by vitamin K absence or antagonist-II (PIVKA-II) for hepatocellular carcinoma screening in Chinese population","volume":"15","author":"Yu","year":"2015","journal-title":"Hepat Mon"},{"issue":"6","key":"2025051000265304500_CIT0030","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1080\/00365521.2018.1459824","article-title":"Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis","volume":"53","author":"Caviglia","year":"2018","journal-title":"Scand J Gastroenterol."},{"issue":"29","key":"2025051000265304500_CIT0031","doi-asserted-by":"publisher","first-page":"e21231","DOI":"10.1097\/MD.0000000000021231","article-title":"Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and\/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer","volume":"99","author":"Chen","year":"2020","journal-title":"Medicine (Baltim)."},{"key":"2025051000265304500_CIT0032","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2147\/CMAR.S239593","article-title":"Increased expression of TAP is predictive of poor prognosis in patients with non-small cell lung cancer","volume":"12","author":"Cheng","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"11","key":"2025051000265304500_CIT0033","doi-asserted-by":"publisher","first-page":"e19382","DOI":"10.1097\/MD.0000000000019382","article-title":"Insights into the role of tumor abnormal protein in early diagnosis of cancer: a prospective cohort study","volume":"99","author":"Li","year":"2020","journal-title":"Medicine (Baltim)."},{"issue":"1","key":"2025051000265304500_CIT0034","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3892\/mco.2016.877","article-title":"Prognostic value of serum tumor abnormal protein in gastric cancer patients","volume":"5","author":"Lan","year":"2016","journal-title":"Mol Clin Oncol"},{"issue":"1-2","key":"2025051000265304500_CIT0035","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0165-0270(92)90040-k","article-title":"Notes on a light and electron microscopic double-labeling method combining anterograde tracing with Phaseolus vulgaris leucoagglutinin and retrograde tracing with cholera toxin subunit B","volume":"45","author":"Bruce","year":"1992","journal-title":"J Neurosci Methods."},{"issue":"4","key":"2025051000265304500_CIT0036","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/s0168-8278(00)00053-2","article-title":"Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status","volume":"34","author":"Trevisani","year":"2001","journal-title":"J Hepatol."},{"key":"2025051000265304500_CIT0037","doi-asserted-by":"publisher","first-page":"m3544","DOI":"10.1136\/bmj.m3544","article-title":"New advances in the diagnosis and management of hepatocellular carcinoma","volume":"371","author":"Yang","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"2025051000265304500_CIT0038","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/3\/297\/61322248\/lmae104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/56\/3\/297\/61322248\/lmae104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T04:27:01Z","timestamp":1746851221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/56\/3\/297\/7941861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,2]]},"published-print":{"date-parts":[[2025,5,9]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmae104","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"type":"print","value":"0007-5027"},{"type":"electronic","value":"1943-7730"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,1,2]]}}}